Sage Therapeutics Inc Reports Results For The Quarter Ended In January 1: Earnings Summary

Sage Therapeutics

30/10/2024 02:52

* SAGE Therapeutics Inc  SAGE.OQ  reported a quarterly
adjusted
loss of $1.53​​ per share for the quarter ended January 1,
higher than the same quarter last year, when the company
reported EPS of $-3.37.  The mean expectation of
nineteen analysts for the quarter was for a loss of $1.53 per
share. Wall Street expected results to range from $-1.74
to $-1.20 per share.
    * Revenue rose 337.1% to $11.87 million from a year ago;
analysts
expected $10.80 million. 
    * SAGE Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.53​.
    * The company reported a quarterly loss of $93.55 million.
    * SAGE Therapeutics Inc shares had risen by 18.3% this
quarter and
lost 60.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 16
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for SAGE Therapeutics
Inc is 10.00 
This summary was machine generated from LSEG data October 30 at
02:51 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.53          -1.53          Met
 Jun. 30 2024      -1.66          -1.70          Missed
 Mar. 31 2024      -1.65          -1.80          Missed
 Dec. 31 2023      -1.28          -1.80          Missed